Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.954,30
-0,19%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Clovis Oncology Inc (CLVS) Clovis Oncology Inc (CLVS) Notizie

CLVS

Clovis Oncology (CLVS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CLVS
DataOraFonteTitoloSimboloCompagnia
01/05/202322:17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CLVSClovis Oncology Inc
10/02/202315:49Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CLVSClovis Oncology Inc
29/12/202215:36Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:CLVSClovis Oncology Inc
12/12/202212:54Dow Jones NewsClovis Oncology Shares Fall Premarket After Bankruptcy FilingNASDAQ:CLVSClovis Oncology Inc
12/12/202206:18Business WireClovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286NASDAQ:CLVSClovis Oncology Inc
09/11/202214:12Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CLVSClovis Oncology Inc
03/11/202221:18Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CLVSClovis Oncology Inc
27/10/202223:05Business WireClovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific RetreatNASDAQ:CLVSClovis Oncology Inc
17/10/202209:45Business WireClovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM CongressNASDAQ:CLVSClovis Oncology Inc
03/10/202213:00Business WireTRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM MutationsNASDAQ:CLVSClovis Oncology Inc
21/09/202214:00Business WireClovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply AgreementNASDAQ:CLVSClovis Oncology Inc
13/09/202214:00Business WireClovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian CancerNASDAQ:CLVSClovis Oncology Inc
12/09/202213:55TipRanksClovis (NASDAQ:CLVS) Jumps After Rubraca Shows Progression-Free Survival in Ovarian CancerNASDAQ:CLVSClovis Oncology Inc
11/09/202216:30Business WireClovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk SubgroupsNASDAQ:CLVSClovis Oncology Inc
09/08/202212:16TipRanksH.C. Wainwright Remains a Hold on Clovis Oncology (CLVS)NASDAQ:CLVSClovis Oncology Inc
08/08/202214:00Business WireClovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development ProgramsNASDAQ:CLVSClovis Oncology Inc
22/07/202215:35TipRanksH.C. Wainwright Maintains a Hold Rating on Clovis Oncology (CLVS)NASDAQ:CLVSClovis Oncology Inc
21/07/202200:06Business WireCORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8NASDAQ:CLVSClovis Oncology Inc
20/07/202222:00Business WireClovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8NASDAQ:CLVSClovis Oncology Inc
08/07/202222:58Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CLVSClovis Oncology Inc
07/07/202222:35Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:CLVSClovis Oncology Inc
28/06/202214:31Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:CLVSClovis Oncology Inc
14/06/202220:00Business WireClovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual MeetingNASDAQ:CLVSClovis Oncology Inc
06/06/202217:55TipRanksClovis Oncology (CLVS) Gets a Hold Rating from H.C. WainwrightNASDAQ:CLVSClovis Oncology Inc
06/06/202214:00Business WireClovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD StatusNASDAQ:CLVSClovis Oncology Inc
05/05/202214:00Business WireClovis Oncology to Present at the BofA Securities 2022 Healthcare ConferenceNASDAQ:CLVSClovis Oncology Inc
05/05/202212:17TipRanksClovis Oncology (CLVS) Receives a Buy from H.C. WainwrightNASDAQ:CLVSClovis Oncology Inc
04/05/202214:00Business WireClovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development ProgramsNASDAQ:CLVSClovis Oncology Inc
28/04/202214:00Business WireClovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual MeetingNASDAQ:CLVSClovis Oncology Inc
27/04/202222:06Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CLVSClovis Oncology Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CLVS

La tua Cronologia

EU
TTGCH
Tagus Soc Titul Creditos...
NASDAQ
ABAPMXX
Hsbc Bank Usa Na Capped ...
NYSE
NZH-C.CL
USOTC
ORSX
Orsus Xelent Technolgies (CE)
LSE
0A6J
Southwestern Energy
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network